Terson syndrome
In 1900, Terson first reported that intracranial hemorrhage could be the cause of vitreous hemorrhage, and believed that this eye-brain syndrome was a sign of subarachnoid hemorrhage, called Terson syndrome.
-
Site of disease:
Eyes, skull and brain -
Infectious :
Not contagious -
Frequent population:
Children with Terson syndrome are larger than adults -
Related symptoms:
Retinal hemorrhage Visual impairment Blood in the vitreous Retinal detachment Fundus hemorrhage and exudation -
Concurrent disease:
Related Drugs
Tranexamic Acid Injection
Indication: 1. This product is mainly used for various bleeding caused by acute or chronic, localized or systemic primary hyperfibrinolysis. For secondary hyperfibrinolytic state caused by disseminated intravascular coagulation, this product is generally not used before heparinization; 2. It is used for traumatic or surgical bleeding in organs rich in plasminogen activators such as the prostate, urethra, lungs, brain, uterus, adrenal glands, and thyroid glands; 3. It is used as an antagonist of tissue plasminogen activator (t-PA), streptokinase, and urokinase; 4. It is used for fibrinolytic bleeding caused by artificial abortion, early placental abruption, stillbirth, and amniotic fluid embolism, as well as menorrhagia caused by pathological local increased fibrinolysis in the uterine cavity; 5. It is used for mild bleeding caused by central nervous system diseases, such as subarachnoid hemorrhage and intracranial aneurysm bleeding. The use of this product for hemostasis is superior to other anti-fibrotic drugs.
Tranexamic Acid Injection
Indication: 1. This product is mainly used for various bleeding caused by acute or chronic, localized or systemic primary hyperfibrinolysis. For secondary hyperfibrinolytic state caused by disseminated intravascular coagulation, this product is generally not used before heparinization; 2. It is used for traumatic or surgical bleeding in organs rich in plasminogen activators such as the prostate, urethra, lungs, brain, uterus, adrenal glands, and thyroid glands; 3. It is used as an antagonist of tissue plasminogen activator (t-PA), streptokinase, and urokinase; 4. It is used for fibrinolytic bleeding caused by artificial abortion, early placental abruption, stillbirth, and amniotic fluid embolism, as well as menorrhagia caused by pathological local increased fibrinolysis in the uterine cavity; 5. It is used for mild bleeding caused by central nervous system diseases, such as subarachnoid hemorrhage and intracranial aneurysm bleeding. The use of this product for hemostasis is superior to other anti-fibrotic drugs.
Manufacturer:
Hunan Dongting Pharmaceutical Co., Ltd.
Related Ingredients